NeuCyte

The high attrition rates of novel drugs in clinical trials is a clear indication that current preclinical testing is failing to predict compounds that will reach the market. NeuCyte, is an early-stage biotechnology company focused on advancing the drug discovery process by using cell based target-identification and drug-discovery platforms. Our technology accelerates the lead drug identification and optimization process. NeuCytes unique human neural platform allows for the evaluation of human specific neural phenotypes that are not identifiable in traditional animal models. This allows for a more reliable predictor of drug efficacy and potential neurotoxicity. NeuCytes all-star staff and scientific advisory...

Cns drug discovery,human in vitro neural disease modeling,neurotox testing,and human neural cells

Neucyte operates in the Pharmaceutical manufacturing industry.

Neucyte's revenue is 11m - 100m

Neucyte has 11 - 50 employees.